AstraZeneca PLC
AZN
$89.10
$0.490.55%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 5.08% | 6.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.08% | 6.40% | |||
| Cost of Revenue | 12.19% | 14.24% | |||
| Gross Profit | 3.55% | 4.85% | |||
| SG&A Expenses | 2.73% | 8.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -23.61% | 36.84% | |||
| Total Operating Expenses | 4.12% | 12.03% | |||
| Operating Income | 8.09% | -8.14% | |||
| Income Before Tax | 3.74% | -8.08% | |||
| Income Tax Expenses | 4.42% | 41.16% | |||
| Earnings from Continuing Operations | 3.55% | -16.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -200.00% | 140.00% | |||
| Net Income | 3.39% | -15.98% | |||
| EBIT | 8.09% | -8.14% | |||
| EBITDA | 9.06% | -4.02% | |||
| EPS Basic | 3.32% | -15.98% | |||
| Normalized Basic EPS | 10.15% | -11.57% | |||
| EPS Diluted | 3.20% | -16.05% | |||
| Normalized Diluted EPS | 10.07% | -11.46% | |||
| Average Basic Shares Outstanding | 0.06% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.13% | -0.13% | |||
| Dividend Per Share | -100.00% | -- | |||
| Payout Ratio | 154.85% | -1.00% | |||